Because there are very few treatments available to safely treat cHI, researchers are looking for better ways to care for people with cHI. Clinical studies like sunRIZE are essential to discovering new treatment options.
The sunRIZE study is being done to see if adding RZ358 to standard medicines (also called “standard‑of‑care” or SOC) helps in controlling blood sugar levels among people with cHI. The study is also investigating other effects RZ358 may have in the body, and the impact RZ358 may have on the daily lives of participants.
All participants will continue to receive their SOC throughout the first part of the study. For participants over 1 year old, most will be randomly selected to get RZ358 (either a low or a high dose) and some will receive a placebo (a medicine that looks like RZ358 but does not have any active drug in it). None of the participants or the study doctors or staff will know during the study which treatment the participants are getting. With this method, researchers will be able to compare just how well RZ358 works when given together with SOC versus SOC by itself.
For caregivers that are interested in having their infant participate in the sunRIZE study, a separate treatment group will allow patients aged 3 months to 1 yr to contribute to advancing the understanding of RZ358 treatment effects on cHI. All infant participants in this treatment group will be given SOC plus RZ358 (starting at the low‑dose of RZ358 and possibly increased to high‑dose of RZ358, if needed). Participants’ guardians, as well as study doctors and staff, will know that the infant is getting RZ358 treatment and how much RZ358 they are receiving.
Understanding how RZ358 works in infants is particularly important since nearly all cHI patients are diagnosed in the first year of life.
Participants must not have
Congenital hyperinsulinism (cHI) is a rare disease in which the pancreas produces too much insulin. Insulin helps control blood sugar levels in the body. Because of high levels of insulin, people with cHI can have frequent episodes of dangerously low blood sugar levels, also called “hypoglycemia”. cHI is the most frequent cause of severe, persistent hypoglycemia in newborns, infants, and children. If not recognized early and treated properly, these episodes of hypoglycemia can lead to serious problems such as seizures, brain damage and death.
“I just have so many questions and concerns about our family’s future with this diagnosis. It’s been a week at the hospital and I’m still nowhere near being able to accept this. I scour literature and the Facebook group and try to find something in anyone’s story that can encourage me but everything I see just drives home the fact we will never lead a normal life and so many of my hopes and dreams for our family and for our little one are shattered.” Banerjee, 2022 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858501/
RZ358 has been specifically developed to treat cHI. It is a type of medicine called a monoclonal antibody—meaning it is a protein created in a research laboratory that can act like the body’s own targeting system to work at a very specific point inside the body. Different monoclonal antibodies have already provided breakthrough treatments in many health conditions.
RZ358 targets the insulin receptor to turn down insulin’s signal to take sugar from the bloodstream, which is particularly helpful to keep the sugar levels in a safer range to protect the brain.
RZ358 is given intravenously (small tube placed into a vein, also called an IV). It takes approximately 30 minutes for the medicine to get through the IV and into the body. The amount of RZ358 given depends on a participant’s weight and to which treatment group they will be randomly assigned.
“Participating in the [RIZE Phase 2b] study was the best thing that could have happened because my daughter was able to regulate her glucose levels much better.”
If you are interested in joining this study (or if you would like your child to take part in the study), you will need to visit one of the study centers nearest to your home.
A study doctor will explain the study to you. If you agree to join or if you agree on behalf of your child, the doctors and site staff will check your or your child’s: overall health, blood sugar levels, and other health conditions through simple tests. Study doctors will also ask you questions about your or your child’s: cHI symptoms, medical history, and medication history to make sure you or your child is eligible to take part in the study. The screening period described above may last for up to 35 days.
If you or your child meet all the criteria of the study and decide to join the study, you or your child will continue the usually prescribed cHI treatment and be given either RZ358 or placebo.
Participants will receive a total of 7 doses of the study treatment over 24 weeks – 3 doses every other week, then 4 monthly doses. Participants will visit a clinical study center at least 8 times during the treatment period. During study site visits, the study doctors will:
At the end of the study, participants will have the option, with the input of the study doctor, to continue into the extended portion of the study and receive RZ358 for a longer time (up to 3 years). For participants that choose to stop the study after the first 24-week portion, there will be 2 monthly visits to the study center after getting the last dose of the assigned study treatment (RZ358 or placebo).
The study will be offered at the sites shown below. Travel support may be provided to the nearest site for qualified participants. Speak with site staff to learn more about available travel support.
See if You are Eligible